Literature DB >> 6137332

Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man.

R H Levy, E A Lane, M Guyot, A Brachet-Liermain, B Cenraud, P Loiseau.   

Abstract

An increase in drug metabolic clearance results in a decrease in concentration of parent drug but the effect on concentration of metabolite has been unclear. The effect of increases in the clearance of parent drug and/or metabolite upon the metabolite concentration, metabolite-to-parent drug concentration ratio, and fraction metabolized is described theoretically. It is shown that several combinations of increases in specific clearances can lead to qualitatively similar effects on steady state concentration of metabolite. The effect of increases in metabolic clearances of the clobazam-norclobazam system caused by carbamazepine treatment was studied in normal volunteers. The steady state concentration of metabolite (norclobazam) increased 1.4-fold and the ratio of metabolite to parent drug increased 4-fold. These effects of carbamazepine on clobazam-norclobazam pharmacokinetics could be a result of five theoretical cases. It is concluded that at least the formation clearance of norclobazam was increased. Carbamazepine treatment caused at least a 4-fold increase in the N-demethylation clearance of clobazam. It was also deduced that, in the baseline state, no more than 70% of the clobazam dose was metabolized to norclobazam, even though the norclobazam concentration was more than twice the clobazam concentration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137332

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.

Authors:  Justin D Lutz; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

Review 2.  Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.

Authors:  Jose de Leon; Edoardo Spina; Francisco J Diaz
Journal:  Ther Drug Monit       Date:  2013-02       Impact factor: 3.681

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Effects of ethanol on drug and metabolite pharmacokinetics.

Authors:  E A Lane; S Guthrie; M Linnoila
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

5.  PharmGKB summary: clobazam pathway, pharmacokinetics.

Authors:  Rachel Huddart; J Steven Leeder; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-04       Impact factor: 2.089

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

7.  Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Authors:  Yoshiaki Yamamoto; Yukitoshi Takahashi; Katsumi Imai; Masaaki Takahashi; Masahiko Nakai; Yushi Inoue; Yoshiyuki Kagawa
Journal:  Eur J Clin Pharmacol       Date:  2014-07-22       Impact factor: 2.953

8.  Mephenytoin stereoselective elimination in the rat: II. Comparison of mephenytoin stereoselective clearance during chronic intravenous and hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 9.  Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.

Authors:  Justin D Lutz; Yasushi Fujioka; Nina Isoherranen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-09       Impact factor: 4.481

10.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Authors:  M V Rudorfer; E A Lane; W H Chang; M D Zhang; W Z Potter
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.